November 12, 2019
The company's clinical study of INOpulse is for the treatment of pulmonary hypertension associated with interstitial lung disease.
November 7, 2019
The company will present data from Cohort 1 of its ongoing Phase 2/3 clinical trial of INOpulse in San Antonio,...
September 16, 2019
The designation has been given by the US Food and Drug Administration to treat patients with idiopathic pulmonary fibrosis.
April 8, 2019
Bellerophon Therapeuetics (NASDAQ:BLPH) has announced it and the US Food and Drug Administration (FDA) have agreed on a regulatory approval...
January 28, 2019
Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse Phase 2b clinical trial...
January 13, 2019
Axsome Therapeutics, Checkpoint Therapeutics, Bellerophon Therapeutics, Enochian Bioscience and Equillium were last week's top gainers.
December 16, 2018
Innovate Biopharmaceuticals, Aridis Pharmaceuticals, Imprimis Pharmaceuticals, Achaogen and SynthoRx were last week's top gainers.